Gen-Probe, Diagnocure Amend Prostate Cancer Test Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Gen-Probe and DiagnoCure said this week that they have amended their 2003 license agreement regarding development and commercialization of a molecular diagnostic test for prostate cancer.

The amended deal establishes new Food and Drug Administration milestones and key distribution arrangements, the partners said in a joint statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.